Press release
Endometrial Cancer Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | GSK, Eisai, Merck, AstraZeneca, Evergreen Therapeutics, MedImmune, On Target Laboratories, Sutro Biopharma, Netris Pharma
"Endometrial Cancer Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Endometrial Cancer Therapeutics Market.
The report provides a detailed description of the Endometrial Cancer drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Endometrial Cancer Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Endometrial Cancer Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Endometrial Cancer therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Endometrial Cancer treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Endometrial Cancer drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Endometrial Cancer treatment market.
Learn More about the Clinical and Commercial Development Activities in the Endometrial Cancer Therapeutics Domain:
https://www.delveinsight.com/report-store/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Endometrial Cancer Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Intravenous
• Oral
• Intramuscular
Molecule Type
Products have been categorized under various Molecule types such as
• Small molecules
• Natural metabolites
• Monoclonal antibodies
Request for Sample PDF to Understand More About the Endometrial Cancer Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Endometrial Cancer Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Endometrial Cancer. Currently, GlaxoSmithKline is leading the therapeutics market with its Endometrial Cancer drug candidates in the mid to advanced stage of clinical development.
Endometrial Cancer Companies in the Therapeutics Market Include:
• GlaxoSmithKline
• Eisai Co Ltd
• MedImmune
• On Target Laboratories
• Sutro Biopharma
• Netris Pharma
And Many Others
Emerging and Marketed Endometrial Cancer Therapies Covered in the Report Include:
• Dostarlimab: GlaxoSmithKline
• Lenvatinib (LENVIMA): Eisai Co Ltd
• KEYTRUDA (pembrolizumab): Merck & Co
• JEMPERLI (dostarlimab-gxly): GlaxoSmithKline Pharmaceuticals
• Lynparza (Olaparib) + Imfinzi DuO-E: AstraZeneca
• EG-007: Evergreen Therapeutics
And Many More
Get an in-depth Assessment of the Emerging Therapies and Endometrial Cancer Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Endometrial Cancer Current Treatment Patterns
4. Endometrial Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Endometrial Cancer Late-Stage Products (Phase-III)
7. Endometrial Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Endometrial Cancer Discontinued Products
13. Endometrial Cancer Product Profiles
14. Endometrial Cancer Companies
15. Endometrial Cancer Drugs
16. Dormant and Discontinued Products
17. Endometrial Cancer Unmet Needs
18. Endometrial Cancer Future Perspectives
19. Endometrial Cancer Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Anaplastic Astrocytoma Market
https://www.delveinsight.com/report-store/anaplastic-astrocytoma-market
Singapore Healthcare Outlook
https://www.delveinsight.com/report-store/singapore-healthcare-outlook-report
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market
https://www.delveinsight.com/report-store/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-market
Chronic Idiopathic Constipation Market
https://www.delveinsight.com/report-store/chronic-idiopathic-constipation-market
Hay Fever Conjunctivitis Market
https://www.delveinsight.com/report-store/hay-fever-conjunctivitis-market
Nasopharyngeal Carcinoma Market
https://www.delveinsight.com/report-store/nasopharyngeal-carcinoma-market
Cerebral Infarction Market
https://www.delveinsight.com/report-store/cerebral-infarction-market
CART-related Neurotoxicity (NT) Market
https://www.delveinsight.com/report-store/cart-related-neurotoxicity-nt-market
Hernia Repair Devices Market
https://www.delveinsight.com/report-store/hernia-repair-devices-market
Bronchial Hyperreactivity Market
https://www.delveinsight.com/report-store/bronchial-hyperreactivity-market
Chronic Focal Epilepsy Market
https://www.delveinsight.com/report-store/chronic-focal-epilepsy-market
Dental Lasers Market
https://www.delveinsight.com/report-store/dental-lasers-market
Down Syndrome Market
https://www.delveinsight.com/report-store/down-syndrome-market
Extracorporeal Circulation System Market
https://www.delveinsight.com/report-store/extracorporeal-circulation-system-market
Failed Back Surgery Syndrome Market
https://www.delveinsight.com/report-store/failed-back-surgery-syndrome-market
Germ Cell Tumor Market
https://www.delveinsight.com/report-store/germ-cell-tumor-market
Hot Flashes Market
https://www.delveinsight.com/report-store/hot-flashes-market
India Healthcare Outlook
https://www.delveinsight.com/report-store/india-healthcare-outlook-report
Insulin Glargine Biosimilar
https://www.delveinsight.com/report-store/insulin-glargine-biosimilar-insight
Listeriosis Market
https://www.delveinsight.com/report-store/listeriosis-market
Liver Angiosarcoma Market
https://www.delveinsight.com/report-store/liver-angiosarcoma-market
Mucopolysaccharidosis I Market
https://www.delveinsight.com/report-store/mucopolysaccharidosis-i-market
Nasolabial Fold Market
https://www.delveinsight.com/report-store/nasolabial-fold-market
Neuroleptic Malignant Syndrome Market
https://www.delveinsight.com/report-store/neuroleptic-malignant-syndrome-market
Pachyonychia Congenita Market
https://www.delveinsight.com/report-store/pachyonychia-congenita-market
Point of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
Reactive Airway Disease Market
https://www.delveinsight.com/report-store/reactive-airway-disease-market
Seborrhea Market
https://www.delveinsight.com/report-store/seborrhea-market
Substance (Drug) Abuse Market
https://www.delveinsight.com/report-store/substance-drug-abuse-market
Synchronous Endometrial and Ovarian Cancer (SEOC) Market
https://www.delveinsight.com/report-store/synchronous-endometrial-and-ovarian-cancer-seoc-market
Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
Urinary Tract Infection Devices Market
https://www.delveinsight.com/report-store/urinary-tract-infection-devices-market
Varicose Veins Market
https://www.delveinsight.com/report-store/varicose-veins-market
Vulvodynia Market
https://www.delveinsight.com/report-store/vulvodynia-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Endometrial Cancer Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | GSK, Eisai, Merck, AstraZeneca, Evergreen Therapeutics, MedImmune, On Target Laboratories, Sutro Biopharma, Netris Pharma here
News-ID: 3153900 • Views: …
More Releases from DelveInsight Business Research LLP
PARP Inhibitor Pipeline Outlook Report 2025: Emerging Therapies, Clinical Develo …
DelveInsight's "PARP inhibitor Pipeline Insights 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the PARP inhibitor pipeline landscape. It covers the PARP inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the PARP inhibitor therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight's comprehensive PARP inhibitor Pipeline…
TGFB Inhibitors Pipeline Outlook Report 2025: Emerging Therapies, Clinical Devel …
DelveInsight's "Transforming Growth Factor Beta Inhibitors Pipeline Insight 2025" report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Transforming Growth Factor Beta Inhibitors pipeline landscape. It covers the Transforming Growth Factor Beta Inhibitors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Transforming Growth Factor Beta Inhibitors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the…
Prostate Cancer Pipeline Outlook Report 2025: Emerging Therapies, Clinical Devel …
DelveInsight's "Prostate Cancer Pipeline Insight 2025" report provides comprehensive insights about 140+ companies and 150+ pipeline drugs in the Prostate Cancer pipeline landscape. It covers the Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Prostate Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest…
PD-1 and PD-L1 Inhibitors Competitive Landscape Report 2025: Emerging Therapies, …
DelveInsight's "PD-1 and PD-L1 Inhibitors Competitive landscape 2025" report provides comprehensive insights about 180+ companies and 200+ drugs in the PD-1 and PD-L1 Inhibitors Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the full insights into the evolving PD-1 and PD-L1 Inhibitors Pipeline and discover which companies are leading the innovation…
More Releases for Endometrial
Rising Prevalence Of Endometrial Cancer Through Advances In The Endometrial Canc …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Endometrial Cancer Treatment Industry Market Size Be by 2025?
In recent years, the market size for endometrial cancer treatment has experienced consistent growth. It is projected to increase from $31.04 billion in 2024 to $32.09 billion in 2025, indicating a compound annual growth rate (CAGR) of…
Rising Prevalence Of Endometrial Cancer Through Advances In The Endometrial Canc …
The Endometrial Cancer Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Endometrial Cancer Treatment Market Size and Projected Growth Rate?
The Endometrial Cancer Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to…
Endometrial Biopsy Cannulae Market 2023
The report presents detailed information regarding the prominent players and potential competitors in the Endometrial Biopsy Cannulae market. It includes comprehensive insights into their worldwide presence, economic performance, strategies, upcoming product releases, research and development initiatives, and a SWOT analysis. Additionally, the report analyses revenue share and contact details for each player.
This comprehensive report aims to evaluate and forecast the market size for Fuel Monitoring Systems. It analyses revenue, growth…
Hysteroscopic Endometrial Resection Market - Transforming Hysteroscopy, Enhancin …
Newark, New Castle, USA - Growth Plus Reports has published a new report on Hysteroscopic Endometrial Resection Market, which includes a detailed analysis based on competitors and important market segments (2023-2031). The Global Hysteroscopic Endometrial Resection provides a thorough analysis of many segments such as opportunities, market size, developments, innovation, sales, and overall growth of leading players. The research is based on primary and secondary statistical data, and it includes…
Endometrial Ablation Market snapshot 2024
Global Endometrial Ablation Market: Snapshot
With the rising prevalence of gynecology disorders, such as polycystic ovarian disease (PCOD), abnormal vaginal bleeding, the global adoption of endometrial ablation procedures has increased significantly, leading to an impressive rise in the worldwide endometrial ablation market. Apart from this, the upswing in the incidence rate of cervical and endometrial cancer in women is also driving the growth of this market substantially across the world.
Download The…
Global Endometrial Ablation Market: Radiofrequency Endometrial Ablation Devices …
With the presence of large players, such as Hologic Corp., Boston Scientific Corp., Cooper Surgical Inc., Ethicon Inc., and Medtronic Plc at the global level, the worldwide market for endometrial ablation demonstrates a highly competitive landscape, finds a new research report by Transparency Market Research (TMR).
The market players are focusing aggressively on developing their offerings technologically, which is likely to lead to price differentiation, resulting in intense rivalry between these…
